GlassScriptPhysician profile
Gregory O Patton
NPI 1184612996
$2,436.88
in general payments reported to CMS, 2019-2025
28 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $233 · 2021: $318 · 2022: $330 · 2023: $402 · 2024: $334 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,075.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $655.41 | 2019-2025 | |
| Astellas Pharma US INC | $271.28 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $222.87 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $154.86 | 2021-2025 | |
| Hologic Sales and Service, LLC | $136.69 | 2022-2024 | Acessa Provu System, Omni Hysteroscope, Novasure |
| Daiichi Sankyo INC. | $128.59 | 2019-2024 | Injectafer |
| Biogen, INC. | $120.61 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $99.30 | 2020-2025 | Slynd |
| Organon LLC | $71.43 | 2021-2023 | Nexplanon |
| Therapeuticsmd, INC. | $70.74 | 2020-2022 | |
| Dexcom, INC. | $54.48 | 2025 | Dexcom G6 Transmitter |
| Aspira Women'S Health INC | $53.53 | 2021 | |
| Amag Pharmaceuticals, INC. | $52.56 | 2019 | |
| Avion Pharmaceuticals | $52.51 | 2019-2021 | |
| Duchesnay USA Incorporated | $42.89 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $40.04 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $39.87 | 2019-2024 | Gardasil 9, Gardasil |
| Convatec INC. | $22.25 | 2023 | |
| Azurity Pharmaceuticals, INC. | $18.33 | 2023 | Adthyza |
| Stryker Corporation | $17.77 | 2023 | |
| Avanos Medical | $17.27 | 2019 | |
| Millicent US INC | $17.18 | 2025 | Femlyv, Intrarosa |
| Acella Pharmaceuticals, LLC | $15.38 | 2025 | NP Thyroid 60 |
| Axonics, INC. | $13.61 | 2020 | |
| Coopersurgical, INC. | $12.01 | 2020 | |
| Allergan, INC. | $12.00 | 2019 | |
| Evofem Biosciences, INC. | $11.95 | 2021 | |
| Lupin INC. | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Patton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.